← FDA DRUG APPROVALS

FDA ANDA · ANDA208915

CINACALCET

Sponsor: CIPLA

APPLICATION
ANDA208915
TYPE
ANDA
ORIGINAL APPROVAL
2018-03-08
LATEST ACTION
2023-12-08
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

CINACALCET HYDROCHLORIDEPrescription
CINACALCET HYDROCHLORIDE EQ 30MG BASE · TABLET · ORAL
CINACALCET HYDROCHLORIDEPrescription
CINACALCET HYDROCHLORIDE EQ 60MG BASE · TABLET · ORAL
CINACALCET HYDROCHLORIDEPrescription
CINACALCET HYDROCHLORIDE EQ 90MG BASE · TABLET · ORAL

Approval history

2023-12-08Labeling · Supplement 11 · standardAP
2020-12-04Labeling · Supplement 3 · standardAP
2020-04-02Labeling · Supplement 2 · standardAP
2018-03-08UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →